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Risto Kerkela,1 Bradley W. Doble,3 Katrina MacAulay,4 Morgan DeCaul,1
Walter J. Koch,1 John Farber,1 James Woodgett,4 Erhe Gao,1 and Thomas Force1
1Thomas

Jefferson University, Philadelphia, Pennsylvania, USA. 2Temple University School of Medicine, Philadelphia, Pennsylvania, USA.
3McMaster Stem Cell and Cancer Research Institute, McMaster University, Hamilton, Ontario, Canada.
4Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.

The glycogen synthase kinase-3 (GSK-3) family of serine/threonine kinases consists of 2 highly related
isoforms, α and β. Although GSK-3β has an important role in cardiac development, much remains unknown
about the function of either GSK-3 isoform in the postnatal heart. Herein, we present what we believe to be the
first studies defining the role of GSK-3α in the mouse heart using gene targeting. Gsk3a–/– mice over 2 months
of age developed progressive cardiomyocyte and cardiac hypertrophy and contractile dysfunction. Following
thoracic aortic constriction in young mice, we observed enhanced hypertrophy that rapidly transitioned to
ventricular dilatation and contractile dysfunction. Surprisingly, markedly impaired β-adrenergic responsiveness was found at both the organ and cellular level. This phenotype was reproduced by acute treatment of WT
cardiomyocytes with a small molecule GSK-3 inhibitor, confirming that the response was not due to a chronic
adaptation to LV dysfunction. Thus, GSK-3α appears to be the central regulator of a striking range of essential processes, including acute and direct positive regulation of β-adrenergic responsiveness. In the absence of
GSK-3α, the heart cannot respond effectively to hemodynamic stress and rapidly fails. Our findings identify
what we believe to be a new paradigm of regulation of β-adrenergic signaling and raise concerns given the rapid
expansion of drug development targeting GSK-3.
Introduction
The glycogen synthase kinase-3 (GSK-3) family consists of 2
isoforms, α and β, which are 98% identical within their kinase
domains but differ substantially in their N- and C-terminal
sequences (1). Unlike most protein kinases, GSK-3 is typically active in unstimulated cells and is inhibited in response to a
variety of inputs (1). Since GSK-3–mediated phosphorylation of
substrates usually leads to inhibition of those substrates, the end
result of stimulus-induced inhibition of GSK-3 is typically activation of its downstream targets. Innumerable factors have been
reported to be bona fide substrates of GSK-3 (2, 3).
Most of the attention on this family has centered on GSK-3β,
which, since its discovery, has been reported to regulate an astonishing variety of cellular processes. However, this bias toward GSK-3β as
the dominant isoform may go back many years to studies in which
mammalian GSK-3β was better able than GSK-3α to rescue the frizzled phenotype in Drosophila, which resulted from a mutation in fly
GSK-3 (Zw3/shaggy) (4, 5). In fact, recent studies done in ES cells in
which Gsk3a, Gsk3b, or both have been deleted demonstrate that the 2
isoforms are entirely redundant in terms of regulating the canonical
Wnt pathway (6). Thus, not until 3 out of 4 alleles of Gsk3a and Gsk3b
are deleted is there any spontaneous activation of Wnt/β-catenin signaling, and not until all 4 are deleted is the activation marked.
However, GSK-3s are clearly not redundant in all functions. For
example, GSK-3α is not able to compensate for loss of GSK-3β
during cardiac development (7). Indeed, the hearts of embryos in
Conflict of interest: The authors have declared that no conflict of interest exists.
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which Gsk3b has been deleted were characterized by a hypertrophic
myopathy that was due primarily to hyperproliferation of cardiomyocytes (7). This led to near obliteration of the RV and LV cavities
and, together with structural defects, including double outlet RV
and ventricular septal defect, common congenital abnormalities in
humans, uniformly led to late embryonic or immediate postnatal
death. Furthermore, based on studies in ES cells in which one or
the other isoform has been deleted, GSK-3β appears to promote
cardiomyocyte differentiation, whereas GSK-3α plays a much
more minor role (3, 7).
Although the above findings clearly demonstrate that
GSK-3β plays a dominant role in cardiac development, the role of
the isoforms in the postnatal heart is not known. This is due to the
fact that all studies to date have used transgenesis, knockin of activated mutants, or nonselective small molecule inhibitors (e.g., BIO)
(8–14). None of these strategies allow one to define the true biology
of GSK-3s or an understanding of isoform-specific effects.
Not surprisingly, some of these studies have reached seemingly
contradictory conclusions, particularly concerning the role of
GSK-3α. For example, work from the same laboratory alternately reported that constitutively active GSK-3α suppressed pressure overload–induced hypertrophy in a transgenic model but
enhanced hypertrophy in a knockin model (13, 14). Further complicating understanding, the strategy used in these models (mutation of the inhibitory serine 21 phosphorylation site of GSK-3α
and serine 9 phosphorylation site of GSK-3β to alanine residues)
blocks only 1 mechanism by which GSK-3α can be inhibited (i.e.,
PI3-kinase–mediated activation of Akt) and does not affect Wntmediated or p38-MAPK–mediated inhibition (15–17). Finally, to
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Figure 1
Deletion of Gsk3a leads to cardiac hypertrophy. (A) Deletion of Gsk3a does not lead to compensatory upregulation of GSK-3β. Immunoblot of
heart lysates from 6-month-old Gsk3a+/+ (WT) and Gsk3a–/– (KO) mice, blotted with anti–GSK-3α (top), anti–GSK-3β (middle), or loading control
(anti-GAPDH, bottom). (B) Cardiomyocyte size determination. Cardiomyocytes were isolated from 6-month-old KO and WT mice, as described
in Methods. Cell area was then determined in 551 KO myocytes from mice (n = 6) and 576 WT myocytes from mice (n = 6), as described in
Methods. #P < 0.01 versus WT. (C) GSK-3α regulates phosphorylation of glycogen synthase, Ser641. Mice were fasted overnight, and then
heart lysates were immunoblotted with anti–phospho–glycogen synthase (GS-pSer641), anti–glycogen synthase (GS), or GAPDH. The image is
representative of findings from WT (n = 6) and KO (n = 6) mice. (D) Dysregulation of mTORC1 in the KO mice. Lysates of hearts from 4-month-old
WT and KO mice were immunoblotted for (top to bottom) phospho–4E-BP1 Thr37/46, phospho–4E-BP1 Ser65, total 4E-BP1, phospho-p70S6K
Thr389, total p70S6K, or GAPDH. Note the increase in phosphorylation of 4E-BP1 at both sites and of p70S6K in the KO.

date, no studies have examined possible metabolic effects of GSK3s and how they might affect cardiac function, even though this
is a critical factor in GSK-3–regulated disease processes, including
glucose intolerance and diabetes (18, 19).
Herein, we used a mouse in which Gsk3a has been deleted (KO)
to define its roles in the heart. We found critical roles for this
kinase in cardiac growth, pathologic hypertrophy, maintenance
of mitochondrial integrity, and regulation of contractile function. Most importantly, we found that the response to β-adrenergic stimulation, which is one of the most critical responses in the
heart to stress, if not the most important one, depends on GSK-3α.
In the absence of GSK-3α, there is a gradual deterioration in
LV function that is dramatically accelerated when the heart is
exposed to hemodynamic stress.
Results
Hypertrophy in the GSK-3α KO. The creation of the GSK-3α KO
mouse was previously described (6, 20). Briefly, a pCAGGS
(chicken β-actin) Cre deleter mouse strain generated by Nagy
(21), which expresses Cre in all tissues, was crossed with the Gsk3a
floxed mouse (exon 2) to generate the KO mice. Subsequently,
the Cre transgene was bred out, and Cre was no longer detectable by RT-PCR in the mice used herein. Importantly, there was
no compensatory upregulation of GSK-3β in the heart following
deletion of Gsk3a (Figure 1A). As previously reported, Gsk3a KO
mice appeared normal at birth (7). However, beginning after 3
months of age, cardiac hypertrophy developed (Tables 1 and 2).
Cardiac hypertrophy was due, at least in part, to cardiomyocyte
hypertrophy, since cardiomyocyte size was significantly increased
in the KO mice (Figure 1B).
The hypertrophy was not due to hypertension, since LV systolic
pressures (LVSPs) were not increased in the KO mice at up to 6
months of age (see below). The hypertrophy was also not likely due
to volume overload, since LV end-diastolic dimension (EDD), as

assessed by echocardiography, was not increased in the KO mice at
up to 6 months of age (Table 2) and LV end-diastolic pressure was not
increased in the KO mice until 6 months of age (data not shown).
Given the key role of GSK-3 in regulating glycogen storage, we
asked whether enhanced glycogen storage, which leads to cardiac
hypertrophy in patients with mutations in the γ2 subunit of AMPK
(22), could account for the hypertrophy in the Gsk3a–/– mice.
Although we did find that GSK-3α regulated phosphorylation status of the critical Ser641 residue of glycogen synthase (Figure 1C)
and, consequently, glycogen storage in the heart, the absolute
amount of glycogen in the heart was small (0.05% of that in the
liver), and the increase compared with WT littermates was minimal (12.5 ± 0.36 vs. 15.7 ± 0.95 mg/g of tissue; P = 0.06). Thus,
increased glycogen storage did not account for the hypertrophy.
We then turned to signaling pathways downstream of GSK-3
that regulate hypertrophic growth. One of these is mTOR complex 1 (mTORC1), the master regulator of protein translation
Table 1
Gravimetric data for the Gsk3a knockout mouse heart
n

BW (g)

HW (mg)

HW/BW ratio

26.8 ± 3.36
27.5 ± 3.13

102.4 ± 10.96
107.9 ± 13.33

3.88 ± 0.128
3.97 ± 0.144

32.7 ± 1.96
35.8 ± 2.56

137.9 ± 11.94
169.9 ± 8.25A

3.96 ± 0.290
4.84 ± 0.249A

35.6 ± 2.04
37.8 ± 2.22

146.3 ± 14.92
184.7 ± 16.19A

4.10 ± 0.273
4.89 ± 0.129A

2 months old
WT
KO

23
25

4 months old
WT
KO

11
14

6 months old
WT
KO

10
21

Values are mean ± SD. AP < 0.05, KO versus WT mice.
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Table 2
Echocardiographic data for the Gsk3a knockout mouse heart

(Figure 3F). Furthermore, in contrast to WT mice, EDD increased
significantly in the KO mice at the
3-week time point, consistent with
n
LV mass (mg)
LVPW;d (mm)
EDD (mm)
ESD (mm)
FS (%)
adverse remodeling occurring early
2 months old
after TAC (Figure 3C). This adverse
WT
18
109.9 ± 11.15
0.80 ± 0.065
4.00 ± 0.245
2.71 ± 0.210
30.12 ± 3.066
remodeling was again associated
KO
17
111.7 ± 17.05
0.82 ± 0.075
4.04 ± 0.341
2.71 ± 0.395
29.97 ± 4.640
with an inability of the KO mice
4 months old
to generate a pressor response to
WT
18
130.2 ± 15.74
0.83 ± 0.092
4.18 ± 0.230
2.66 ± 0.286
30.89 ± 3.399
TAC (Figure 3D). The KO hearts
0.94 ± 0.062B
4.20 ± 0.294
2.67 ± 0.398
28.47 ± 3.291A
KO
17
150.7 ± 26.18B
were also notable for significant
6 months old
replacement fibrosis, consistent
with cell loss. This was widespread
WT
23
139.0 ± 21.00
0.88 ± 0.087
4.23 ± 0.317
2.72 ± 0.352
35.93 ± 5.011
1.00 ± 0.096A
4.30 ± 0.315
2.98 ± 0.322A 30.22 ± 3.534B
KO
23
172.1 ± 29.11B
and involved approximately 14%
of the surface area of the LV of the
LV mass (in mg) was calculated on M-mode and 2-dimensional echocardiography. Values are mean ± SD.
KO hearts (Figure 3F).
LVPW;d, diastolic LV posterior wall; ESD, end-systolic dimension; FS, fractional shortening. AP < 0.05,
BP < 0.01 KO versus WT mice.
Contractile dysfunction in the KO
heart. Not only was there marked
LV dysfunction after TAC in the
that is inhibited following GSK-3–mediated phosphorylation KO heart, modest LV dysfunction was also apparent in the nonof Tsc2 (23). We found significant activation of mTORC1 based stressed KO heart, as assessed by echocardiography at both 4
on enhanced phosphorylation of 2 of its substrates, 4E-BP1 and and 6 months of age (Table 2). To get a sense of the factors that
p70S6 kinase (Figure 1D). Thus GSK-3α is a key negative input might contribute to the LV dysfunction, we examined transmisinto mTORC1 signaling, and loss of GSK-3α leads to inappropri- sion EMs from the hearts of 6-month-old KO mice. We found
ate activation of mTOR in the heart. In contrast, we saw no acti- striking abnormalities of mitochondrial structure, characterized
vation of other hypertrophic signaling pathways including Akt by markedly swollen mitochondria, containing only remnants
(data not shown) and p38 MAPK, but did find modest activation of cristae (Figure 4, A and B). These findings were relatively
of ERK1/2 in the basal state (see below).
widespread and strongly suggested opening of the mitochonPressure overload hypertrophy in the GSK-3α KO mice. We then drial permeability transition pore. Of note, these findings were
examined the effect of deletion of Gsk3a on the response to pres- not present in the 2-month-old or 4-month-old hearts (data not
sure overload induced by transverse aortic constriction (TAC) at shown). Thus, the mitochondrial abnormalities likely exacerbat4 months of age. Mice that underwent TAC had an increase in ed the LV dysfunction seen in the 6-month-old mice, but other
hypertrophy that was more pronounced in KO compared with processes were also involved, since the mitochondrial abnormalWT mice (Figure 2A). This was associated with increased expres- ities were not present at the earlier time points.
sion of atrial natriuretic peptide (3.7-fold in KO mice undergoing
We were most struck by the inability of the KO heart to mount
TAC [KO/TAC] vs. WT mice undergoing TAC [WT/TAC]; P = 0.01) a contractile response in the setting of pressure stress, and we
and a trend toward increased brain natriuretic peptide (1.5-fold in explored potential mechanisms. Since the β-adrenergic system
KO/TAC vs. WT/TAC; P = 0.06).
is critical for the heart’s response to stress, we examined adrenWhen we plotted heart weight/body weight (HW/BW) versus ergic responsiveness in the hearts of the 6-month-old KO mice
LVSP, the KO mice had much higher HW/BW at significantly exposed to graded isoproterenol infusion. These studies were
lower systolic pressures (Figure 2, B and C). This was associ- done in mice in the basal state (i.e., in the absence of prior TAC).
ated with reduced fractional shortening (Figure 2D) and more We found a significant reduction in the response of the KO heart
markedly reduced maximal first derivative of LV pressure rise to isoproterenol compared with that of the WT heart (Figure 4,
(+dP/dt) and fall (–dP/dt) (Figure 2, E and F). Since the degree of C–F). The LVSP response was reduced, albeit not significantly
TAC was the same in WT and KO mice, the data, taken together, (Figure 4C), but there was a markedly blunted +dP/dt (Figure
are consistent with an enhanced hypertrophic response and an 4D) and –dP/dt (Figure 4E) response in the KO compared with
inability of the heart of the GSK-3α KO mouse to generate a the WT heart. The heart rate response to isoproterenol was also
pressor response to TAC.
blunted (Figure 4F).
Although substantially greater in the KO mice, the full magniAt 2 months of age, despite echocardiographic fractional shorttude of the difference in the hypertrophic response between WT ening being normal (Figure 3B and Tables 1 and 2), the contractile
and KO mice was somewhat difficult to compare in the 4-month- responses to β-adrenergic stimulation (LVSP and +dP/dt) were sigold mice, given the baseline differences in heart weight (Tables 1 nificantly depressed (Figure 5, A and B). –dP/dt was also reduced
and 2 and Figure 2A). Therefore, we used TAC in 2-month-old (Figure 5C). The depression of β-adrenergic responsiveness was
mice, a time at which there are no differences between WT and KO also evident at the single cell level, though it did not reach statismice in baseline LV mass (Table 1 and Figure 3A). We then followed tical significance in the myocytes isolated from 2-month-old KO
the mice with weekly echocardiography for 3 weeks. Within 1 week, mice (Figure 6, A and B).
calculated LV mass in KO and WT mice started to diverge, and
We then explored mechanisms of the impaired response to
at 2 and 3 weeks after TAC, the differences were statistically sig- β-adrenergic stimulation. We first wanted to rule out the possinificant (Figure 3, A and E). In contrast to the WT mice, fractional bility that the alterations in β-adrenergic responsiveness were a
shortening progressively fell over the 3-week period in the KO mice consequence, as opposed to the cause, of the LV dysfunction. That
2282
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Figure 2
Exaggerated hypertrophy and impaired cardiac function in the 4-month-old KO mouse subjected to pressure stress. Four-month-old WT and KO
mice were subjected to TAC or sham TAC for 3 weeks, as described in Methods. (A) At sacrifice, HW/BW ratios (a measure of cardiac hypertrophy) were determined. (B) HW/BW is plotted as the dependent variable, with LVSP as the independent variable. Note the marked increase
in HW/BW at all LVSPs for the KO mice (black triangles) when compared with WT mice (red circles). Also note that the KO mice were unable to
generate LVSPs of more than 110 mmHg. LVSP (C), fractional shortening (FS) (D), +dP/dt (E), and –dP/dt (F) are shown graphically. Note that
all functional parameters are depressed in the KO mice. n = 7 WT and 9 KO sham mice; n = 10 WT/TAC and 13 KO/TAC (A); n = 19 WT/TAC
and 16 KO/TAC (B); n = 6 WT and 7 KO sham mice; n = 10 WT/TAC and 5 KO/TAC (C–F).

is, we wanted to exclude an intrinsic abnormality of the myocyte
leading to the decreased responsiveness. Therefore, we treated
4-month-old WT and KO mice with NKH477, a water soluble forskolin derivative that increases cAMP levels in the heart by directly
activating adenylyl cyclase (24). Graded infusion of NKH477 markedly increased cAMP levels in the heart, and the increase was com-

parable in WT versus KO mice (Figure 7A). Furthermore, cardiac
responsiveness to increases in cAMP was equivalent in WT versus
KO mice (Figure 7, B–E), ruling out an intrinsic contractile defect
as the cause of the reduced responsiveness in the KO.
We then asked whether the defect in β-adrenergic responsiveness was due to an impairment in cAMP generation. We
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Figure 3
TAC in 2-month-old KO mice. Mice underwent echocardiography
and then were subjected to TAC or sham TAC. Mice were followed
with weekly echocardiography, until sacrifice at 3 weeks after TAC.
(A) LV mass. Note the exaggerated hypertrophic response in the
KO mice. Black triangles represent WT mice subjected to TAC; red
circles represent KO mice subjected to TAC; and green and blue
squares represent WT and KO shams, respectively. (B) Fractional
shortening in the KO mice progressively declined over the 3 weeks
after TAC, whereas fractional shortening in the WT mice remained
stable. (C) EDD progressively declined in WT and KO mice for the
first 2 weeks but then increased sharply in the KO mice, consistent
with adverse remodeling/dilatation. (A–C) P values are for the comparison between WT versus KO mice subjected to TAC. n = 8 WT
and 8 KO sham mice; n = 20 WT/TAC and 20 KO/TAC. (D) LVSP,
measured by invasive hemodynamic evaluation, was decreased in
the KO mice subjected to TAC. n = 8 WT and 8 KO sham mice;
n = 11 WT/TAC and 9 KO/TAC. (E) Morphometrics (hypertrophy).
HW/BW was determined at sacrifice in KO and WT mice undergoing
TAC or sham surgery. n = 8 WT and 8 KO sham mice; n = 9 WT/TAC
and 11 KO/TAC. (F) Fibrosis in the KO mice. WT and KO mice that
underwent TAC were sacrificed at 3 weeks. Sections of heart tissue
were stained with Masson’s trichrome. The percentage of fibrosis
was determined from 10 random images taken from each of 4 KO
and 4 WT mice. Original magnification, ×200.

examined cAMP production in response to isoproterenol infusion in the KO mouse and found that it was markedly reduced
compared with that of the WT mouse, both in the heart in vivo
(Figure 8A) and in cardiomyocytes isolated from the KO mouse
(Figure 8B). To confirm that the dysregulation of cAMP production in the KO mouse was due to a direct effect of deletion of
Gsk3a, we used SB415286, a relatively selective, small molecule
inhibitor of GSK-3 (25, 26). Pretreatment of WT cardiomyocytes
for 30 minutes with SB415286 led to a significant reduction in
the contractile response to isoproterenol, mimicking the findings in the KO cells (Figure 8C). Furthermore, SB415286 significantly blunted isoproterenol-induced cAMP production in
neonatal rat ventricular myocytes (NRVMs), although the cells
were comparable in their ability to generate cAMP following forskolin (Figure 8D).
We then explored the consequences of the impaired cAMP production on downstream signaling. We first examined a central
target of PKA, phospholamban (PLN), in 2-month-old mice.
Isoproterenol-induced phosphorylation of PLN at the PKA (and
CamKII) sites was markedly reduced in the KO mice (Figure 8E).
These alterations in β-adrenergic–mediated PLN phosphorylation can be expected to lead to inhibition of SERCA2 and, if
sustained, to impaired calcium handling and, eventually, contractile dysfunction.
Based on our studies, we knew that the defect in cAMP production was upstream of adenylyl cyclase and therefore was likely
very proximal in the signaling cascade. A parallel signaling pathway to the adenylyl cyclase/cAMP/PKA pathway that is typically
activated when the adenylyl cyclase/cAMP response is downregulated by β-arrestin involves β-arrestin–mediated internalization
of receptor and activation of ERK1/2 (27, 28). Although ERK1/2
was only minimally activated in the basal state in the KO hearts,
isoproterenol-induced ERK1/2 activation was significantly
increased in the KO mice (Figure 8F).
Our studies, taken together, demonstrate that β-adrenergic
responsiveness is directly regulated by GSK-3α, and GSK-3α–medi-

ated positive regulation of β-adrenergic responsiveness is essential
to the heart’s adaptation to stress. In the absence of GSK-3α, the
stressed LV rapidly remodels and fails.
Discussion
In this manuscript, we identify GSK-3α as a critical regulator of
hypertrophic growth of the nonstressed heart, of the hypertrophic response to pressure load, and of maintenance of contractile
function, particularly in the setting of stress. In the absence of
GSK-3α, a spontaneous cardiomyopathy develops that is characterized by relatively marked hypertrophy and modest LV dysfunction, with striking mitochondrial structural abnormalities later
in life. Most importantly, we find that GSK-3α is a critical and
direct regulator of β-adrenergic responsiveness. In the absence of
GSK-3α, the LV is unable to adapt to pressure stress, leading to a
rapid deterioration in function and to decompensation, including
a striking inability to sustain a pressor response. This culminates
in adverse remodeling with LV dilatation. How does deletion of
Gsk3a lead to these phenotypes?
GSK-3α regulates hypertrophy. The role of GSK-3β in cardiac hypertrophy has been examined extensively by several groups, and the
vast majority of studies have found that expression of either WT or
a constitutively active S9A mutant repressed hypertrophy (8–14).
However, based on studies with overexpression of a dominant
inhibitory mutant of GSK-3β, which showed no enhancement
of hypertrophy following TAC, it was not clear what role, if any,
inhibition of GSK-3β played in the response (12). Findings with
GSK-3α have been even less clear. Whereas a constitutively active
transgenic repressed the hypertrophic response to TAC, the same
mutant expressed in a knockin model showed an increased hypertrophic response (13, 14). These disparate and confusing findings,
which led Sugden et al. to state “we just do not know whether to
inhibit or activate GSK-3, or simply not to interfere” (29), highlight
the need to examine loss-of-function approaches that do not rely
on transgenesis. Our data clearly identify a key role for GSK-3α
as a negative regulator of hypertrophic growth, whether it be in
response to stress or not.
In screening for mechanisms by which GSK-3α regulates hypertrophy, we identified mTORC1 as a key target of the kinase, and
loss of GSK-3α cannot be compensated for by GSK-3β, in regards
to this pathway. This is surprising, since the few studies done to
date have focused on GSK-3β and its role in regulating mTORC1
downstream of Wnt signaling (30, 31). Our studies identify GSK-3α
as a central regulator of mTORC1 in hypertrophic signaling. In the
absence of GSK-3α, activity of mTORC1 is significantly increased.
Given the critical role played by mTORC1 in regulating the protein
translation machinery (30), this is very likely to be a key mechanism
by which GSK-3α regulates the hypertrophic response. In addition
to dysregulation of mTORC1, it is likely that the contractile dysfunction seen, especially later in the life of the KO mouse, plays a
role in the increased hypertrophy as a maladaptive response.
GSK-3α regulates contractile function. Prior studies examining
effects of GSK-3s on TAC-induced LV dysfunction have suggested that increased activity of GSK-3α, by either transgenesis
or knockin, led to declines in LV function, suggesting GSK-3α
signaling is detrimental (13, 14). In distinct contrast, our lossof-function studies identify a clear and critical role for GSK-3α
in preserving LV function in the setting of pressure stress. In
the presence of GSK-3α, hearts developed compensated hypertrophy in response to TAC, whereas in the absence of GSK-3α,
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Figure 4
Ultrastructural abnormalities and impaired β-adrenergic responsiveness in the KO mouse. (A and B) Mitochondrial structural abnormalities in
the KO mouse. Six-month-old WT (A) and KO (B) mouse hearts were fixed and processed for transmission EM. In the KO, images show marked
swelling of many mitochondria, with only remnants of cristae remaining. For comparison, several normal mitochondria are scattered throughout
the section and are also evident in A. Original magnification, ×5,000. (C–F) Impaired response to graded isoproterenol (ISO) infusion in 6-monthold KO versus WT mice. Mice were subjected to graded isoproterenol infusion, as described in Methods. LVSP (C), +dP/dt (D), –dP/dt (E), and
heart rate (HR) (F) responses are shown. P values, comparing KO to WT mice, are displayed for each of the doses of isoproterenol. n = 8 WT
and 13 KO mice. bs, basal.

the hearts undergo striking and accelerated adverse remodeling, with decompensation. While the marked disruption of
mitochondrial structural integrity may have played a role in
the LV dysfunction, given the late appearance of this finding
(at 6 months), this is clearly not the primary defect. Rather, we
believe that our studies identify the critical mechanism underlying the protective effects of GSK-3α in the stressed heart to be
maintenance of β-adrenergic responsiveness. In the absence of
GSK-3α, there is marked dysregulation of β-adrenergic signaling that results in markedly reduced phosphorylation of PLN.
2286

The altered β-adrenergic signaling is apparent prior to the mitochondrial abnormalities and prior to hypertrophy, suggesting it
is not a secondary response. This is supported by the findings
with the forskolin derivative, NKH477 (in response to which the
KO mouse had a comparable increase in contractile performance
to that of the WT mouse), and with the small molecule inhibitor
that acutely recapitulated the altered β-adrenergic responsiveness in WT mouse cardiomyocytes and in NRVMs.
Our studies indicate that GSK-3α interacts with the β-adrenergic system above the level of PKA, since cAMP production is
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Figure 5
Impaired response to graded isoproterenol infusion in 2-month-old KO versus WT mice. LVSP (A), +dP/dt (B), and –dP/dt (C) were all reduced
in the KO mice. P values, comparing KO to WT mice, are displayed for each of the doses of isoproterenol. n = 5 WT and 7 KO mice.

reduced in the KO mice, and above the level of adenylyl cyclase,
since forskolin-induced cAMP production was not reduced
by treatment of WT cardiomyocytes with the GSK-3 inhibitor
(Figure 8D). Thus the site of interaction is very proximal, presumably at the receptor/G protein–coupled receptor kinase/β-arrestin
level. The decreased β-adrenergic responsiveness, taken together
with enhanced ERK1/2 activation in the KO mouse, suggests
increased β-arrestin activity is involved, since β-arrestin leads to
both downregulation of β-adrenergic signaling through Gs/adenylyl cyclase/cAMP and increased ERK1/2 signaling via increased
internalization of receptors and ERKs.
The physiological role of this pathway seems clear: GSK-3α
normally serves as a positive feedback loop to enhance β-adrenergic signaling. Given that PKA can phosphorylate GSK-3α,
thereby inhibiting the kinase (32, 33), this would provide a
mechanism for limiting β-adrenergic signaling. Obviously, however, if the inhibition is marked and sustained, serious adverse
consequences can result.
Potential clinical implications and conclusions. Our data underline
the critical role that GSK-3α plays in the heart’s response to
stress. This is a significant concern, given the proposed use of
inhibitors of GSK-3 as insulin sensitizers and as agents to treat
bipolar disorders and a host of other disease states, including
neurodegenerative disorders and ischemic injury (2, 18, 19, 25,

34, 35). On the other hand, in patients with preserved LV function, moderate inhibition of GSK-3α could potentially be used
as a novel strategy to achieve β-blockade, without leading to
the well-described β-blocker–induced deteriorations in glucose
control (36). However, given our findings in the KO mouse,
the toxic-to-therapeutic ratio of any such inhibitor would be
a major concern.
In summary, we believe we have identified a novel and central
role for GSK-3α in regulating contractile function, particularly in
the setting of stress, and this is mediated via direct regulation of
the β-adrenergic signaling pathway.
Methods
Antibodies. Antibodies used were directed against GSK-3α (catalog 9338),
GSK-3β (catalog 9315), glycogen synthase (catalog 3893), glycogen synthase phosphorylated at Ser641 (catalog 3891), elongation factor 4Ebinding protein 1 (4E-BP1) (catalog 9644), 4E-BP1 phosphorylated
at Thr37/46 (catalog 9459), 4E-BP1 phosphorylated at Ser65 (catalog
9451), and p70S6K phosphorylated at Thr389 (catalog 9206) (all from
Cell Signaling Technology). p70S6K (catalog 611260) was from BD Biosciences — Transduction Laboratories. PLN, clone 1 (catalog 05-205) was
from Millipore. PLN phosphorylated at Ser16 (catalog A010-12) or at
Thr17 (catalog A010-13) were from Badrilla Ltd. GAPDH (catalog RDITRK5D4-6C5) was from Research Diagnostics.
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Figure 6
Contractile function of cardiomyocytes
isolated from WT and KO mice. (A and
B) Cardiomyocytes were isolated from
4-month-old (A) and 2-month-old (B) WT
and KO mice, as described in Methods.
Basal and isoproterenol-stimulated fractional shortening were determined at a
5 × 10–7 M concentration of isoproterenol.
Representative tracings from WT and KO
cells and quantification are shown graphically. (A) Quantification is derived from 14
WT and 14 KO cells derived from mice
(n = 6). (B) Quantification is from 23 WT
and 23 KO cells derived from mice (n = 6).

Chemicals. The GSK-3 inhibitor, SB415286 (catalog S3567), the adenylyl cyclase activator, forskolin (catalog F6886), and the protease and
phosphatase inhibitor cocktails (catalog P8430, P2850) were from SigmaAldrich. Isoproterenol was from Hospira (catalog 0409-1410-05).
Immunoblotting. LV tissue was homogenized in 10 volumes of lysis
buffer (50 mM Tris-HCl [pH 7.4]), 150 mM NaCl, 1 mM EDTA, 0.25%
sodium deoxycholate, 1% NP-40, with the protease inhibitor cocktail
and phosphatase inhibitor cocktail present. After homogenization, the
homogenates were centrifuged at 15,000 g for 15 minutes and separated
into NP-40–soluble supernatant and insoluble pellet. Protein concentration in the supernatant was quantified with the bicinchoninic acid protein
assay (catalog 23225; Pierce). Equal amounts of proteins were subjected
to SDS-PAGE and subsequently were transferred to nitrocellulose membranes. Primary antibody incubations were performed at 1:1,000 dilution.
All incubations were done at 4°C, overnight. The secondary antibody used
was Alexa Fluor 680 (Molecular Probes), at 1:3,000 dilution for 1 hour at
room temperature. Membranes were scanned with the Odyssey Infrared
Imaging System (LI-COR).
Myocyte isolation and determination of cardiomyocyte surface area. Mouse LV
myocytes were isolated as previously described (37, 38). The percentage of
rod-shaped myocytes was greater than 70%. Isolated cardiomyocytes were
fixed in 0.1 M PBS containing 2% paraformaldehyde and 2.5% glutaraldehyde. A 30 μl suspension of isolated myocytes were loaded onto positively
charged slides and air dried. Myocytes were then placed in 0.1 M glycine
in PBS for 30 minutes and then were washed with PBS. Cells were permeabilized in 1% Triton X-100 in PBS (pH 7.2) at room temperature for
20 minutes. Cells were then washed in PBS and incubated in 10% Wheat
Germ Agglutinin (catalog F49; Biomeda) in PBS with 2% BSA for 1 hour.
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Slides were washed 3 times with PBS, for 10 minutes each. Slides were then
coated with Immo-Mount Mounting Medium for fluorescence (catalog
H-1000; Vector). The surface area of cardiomyocytes was then quantified
using NIS-Elements Imaging Software (Nikon) (39).
Contractile function in isolated cardiomyocytes. Ventricular myocytes were isolated as described above. Myocytes were maintained at room temperature
in 5% CO2 and 95% O2 and were used within 8 hours of isolation. Myocytes
were placed in a chamber mounted on an inverted Nikon microscope and
perfused with Tyrode’s solution containing 1 mM Ca2+. Cells were paced
at 1 Hz and contractions were measured with a video edge detector as
described previously (37, 38, 40).
cAMP assay. For determination of cAMP content, we used the EIA Kit
for Cell and Tissue Lysates from BIOMOL (catalog AK-205). Briefly, to
determine the level of cAMP in the heart, LV tissue was homogenized in 10
volumes of 0.1 M hydrochloric acid. For determination of cAMP content
in isolated mouse LV myocytes and NRVMs, 106 cells were sonicated in
300 μl of 0.1 M hydrochloric acid. Thereafter, the procedure followed the
manufacturer’s instructions.
Echocardiographic and hemodynamic analysis of cardiac function. Transthoracic 2-dimensional echocardiography (TTE) was performed in anesthetized
(2% inhaled isoflurane) WT and Gsk3a–/– (KO) mice with a 12-MHz probe
(39, 41). TTE in M-mode was carried out in the parasternal short-axis
view to assess LV end-diastolic and end-systolic diameters and function
(assessed as fractional shortening).
For in vivo hemodynamic measurements, a 1.4 French micromanometer-tipped catheter (SPR-671; Millar Instruments Inc.) was inserted
into the right carotid artery and advanced into the LV of mice that
were lightly anesthetized (i.e., maintained spontaneous respirations)
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Figure 7
Normal contractile function in the KO mice following direct activation of adenylyl cyclase. (A) cAMP production in 4-month-old WT and KO hearts,
following graded NKH477 infusion, as described in Methods. n = 5 WT and 5 KO control hearts; n = 7 WT and 6 KO hearts treated with NKH477.
(B–E) Hemodynamic response to graded NKH477 infusion. LVSP (B), +dP/dt (C), -dP/dt (D), and heart rate (E). BL, baseline measurement prior
to administration of NKH477 versus vehicle. n = 9 WT and 7 KO hearts.

with tribromoethanol/amylene hydrate (2.5% wt/vol, 8 μl/g injected
intraperitoneal; Avertin). Hemodynamic parameters, including heart
rate, LV end-diastolic pressure, and +dP/dt and –dP/dt, were recorded in
closed-chest mode, both at baseline and in response to increasing doses
of isoproterenol (0.1, 0.5, 1, 5, and 10 ng), administered via cannulation
of the right internal jugular vein (42).
For the studies with NKH477 (catalog 1063; TOCRIS), mice were
anesthetized and instrumented as above. NKH477 was dissolved in
PBS and was administered in doses of 1, 10, 100, and 1,000 μg/kg in

5-minute intervals, thereby allowing peak contractile function to be
reached prior to dose escalation. Hemodynamic parameters were exactly as described above.
TAC. TAC was performed as previously described (39). Briefly, mice
were sedated with isoflurane (induction, 3%; maintenance, 1.5%) and
anesthetized to a surgical plane with intraperitoneal ketamine (50 mg/kg)
and xylazine (2.5 mg/kg). Anesthetized mice were intubated, and a
midline cervical incision was made to expose the trachea and carotid
arteries. A blunt 20-gauge needle was inserted into the trachea and con-
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Figure 8
GSK-3α regulates isoproterenol-induced cAMP production. (A–C) Studies were in 4-month-old mice. (A) cAMP production in the intact mouse
heart. KO and WT mice were injected with isoproterenol (1 ng/g BW) versus vehicle. Fifteen minutes later, hearts were excised, and cAMP production was determined. n = 4 mice per condition. (B) cAMP production in response to vehicle versus isoproterenol (5 μM, 15 minutes) in cardiomyocytes isolated from KO and WT mice (n = 6), with 4 × 105 myocytes per assay. LVM, LV myocyte. (C) Inhibition of isoproterenol-induced contractile function by a GSK-3 inhibitor. Cardiomyocytes were isolated from WT and KO mice (n = 6). Fractional shortening was determined at baseline,
after isoproterenol (5 μM, 10 minutes), and in WT cells pretreated with SB415286 (10 μM, 60 minutes). Contractile function increased with
isoproterenol in WT cells but not in KO cells or SB415286-treated WT cells. n = 14 cells for WT and KO mice; n = 12 cells for WT plus SB415286
mice. (D) SB415286 blocks cAMP production in NRVMs. NRVMs were pretreated with SB415286 or vehicle, followed by isoproterenol versus
vehicle. SB415286 reduced isoproterenol-induced cAMP production but not forskolin-induced cAMP production. (E) Reduced isoproterenolinduced phosphorylation of PLN in the KO mice. Two-month-old WT and KO mice underwent isoproterenol infusion (1 μg/kg BW) for 15 minutes.
Lysates were immunoblotted for PLN phosphorylated at Ser16 (PKA site), Thr17 (CamKII site), total PLN, and GAPDH. (F) Increased isoproterenol-induced ERK1/2 activation in the KO mice. Mice were treated with isoproterenol versus vehicle as above, and cell lysates were
immunoblotted for phospho-ERK1/2, total ERK1/2, phospho-p38, total p38, or GAPDH.

nected to a volume-cycled rodent ventilator on supplemental oxygen
at a rate of 1 l/min, with a respiratory rate of 140 breaths/min. Aortic
constriction was performed by tying a 7-0 nylon suture ligature against
a 27-gauge needle. The needle was then promptly removed to yield a
constriction of approximately 0.4 mm in diameter. LVSP was determined by in vivo hemodynamics, with a high fidelity pressure transducer advanced to the LV.
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Transmission electron microscopy. Transmission electron microscopy was
performed as previously described (41, 43).
Statistics. Comparisons between 2 groups were performed using 2-tailed
Student’s t test. Comparisons between multiple groups were performed
using 1-way ANOVA with Holm-Sidak post-test using SigmaStat software
(Systat). All data are presented as mean ± SEM, except the tables, which are
mean ± SD. A P value of less than 0.05 was considered significant.
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